Scarica l'app Stockscreener
20.12
4.23%
0.95
Dopo l'orario di chiusura:
19.87
-0.25
-1.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Precedente Chiudi:
$19.17
Aprire:
$19.45
Volume 24 ore:
376.40K
Relative Volume:
1.84
Capitalizzazione di mercato:
$66.66M
Reddito:
$7.97M
Utile/perdita netta:
$-75.74M
Rapporto P/E:
-10.53
EPS:
-1.91
Flusso di cassa netto:
$-85.33M
1 W Prestazione:
+42.82%
1M Prestazione:
+175.59%
6M Prestazione:
+16.08%
1 anno Prestazione:
+16.50%
Intervallo 1D:
$17.85
$20.15
Intervallo di 1 settimana:
$14.09
$21.89
Portata 52W:
$6.76
$30.00
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Nome
Aligos Therapeutics Inc
Settore
Industria
Telefono
(800) 466-6059
Indirizzo
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Confronta ALGS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ALGS | 20.12 | 66.66M | 7.97M | -75.74M | -85.33M | -1.91 |
| VRTX | 467.12 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.38 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-01-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-09 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Ripresa | Piper Sandler | Overweight |
| 2020-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Iniziato | JP Morgan | Overweight |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
EcoR1 Capital, LLC Increases Stake in Aligos Therapeutics Inc - GuruFocus.com
ARMISTICE CAPITAL, LLC Expands Stake in Aligos Therapeutics Inc - GuruFocus.com
Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Expands By 46.5% - MarketBeat
Aligos Therapeutics Inc (ALGS) Quarterly 10-Q Report - Quartz
U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn
Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from HC Wainwright - Defense World
Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations - Yahoo Canada Finance
Aligos Therapeutics Reports Q3 2024 Progress - TipRanks
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - The Manila Times
Aligos Reports 46% Liver Fat Reduction in MASH Trial; Q3 Loss Widens to $19.3M | ALGS Stock News - StockTitan
Aligos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 - The Manila Times
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Drop in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.4% – Here’s What Happened - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 5.4%Here's What Happened - MarketBeat
HC Wainwright Reiterates Buy Rating for Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Aligos Therapeutics' (ALGS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 - The Manila Times
Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH) - 2 Minute Medicine
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap UpWhat's Next? - MarketBeat
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 202 - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 8.4%Should You Sell? - MarketBeat
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Increase in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Trading 4.9% HigherStill a Buy? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges By Investing.com - Investing.com South Africa
Aligos Therapeutics (NASDAQ:ALGS) Hits New 1-Year LowWhat's Next? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges - Investing.com Australia
When the Price of (ALGS) Talks, People Listen - Stock Traders Daily
Aligos TherapeuticsIt's All About Chronic Hepatitis B - RTTNews
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 6.2%Should You Sell? - MarketBeat
Aligos Therapeutics appoints new VP of Business Development By Investing.com - Investing.com Australia
Aligos Therapeutics appoints new VP of Business Development - Investing.com
Aligos Therapeutics Appoints David Perry as Vice President of Business Development - The Manila Times
Aligos Therapeutics to Present at Investor Conferences in October - The Manila Times
(ALGS) Investment Analysis and Advice - Stock Traders Daily
Aligos Therapeutics keeps stock target, overweight rating on promising data By Investing.com - Investing.com Australia
Aligos Therapeutics names new chief medical officer By Investing.com - Investing.com Australia
Aligos Therapeutics keeps stock target, overweight rating on promising data - Investing.com
ALGSAligos Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aligos Therapeutics Inc Azioni (ALGS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.27%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):